Calidi Biotherapeutics (CLDI) Total Current Liabilities (2021 - 2025)

Calidi Biotherapeutics has reported Total Current Liabilities for 5 years, with the latest figure at $3.9 million in Q4 2025.

• For the quarter ending Q4 2025, Total Current Liabilities fell 58.56% year-over-year to $3.9 million; the trailing twelve-month figure through Dec 2025 stood at $3.9 million (down 58.56% YoY), and the FY2025 full-year result was $3.9 million, down 58.56% from the prior year.
• Total Current Liabilities for Q4 2025 stood at $3.9 million, down from $5.2 million in the prior quarter.
• The five-year high for Total Current Liabilities was $43.0 million in Q4 2022, with the low at $373661.0 in Q2 2022.
• Average Total Current Liabilities over 5 years is $8.8 million, with a median of $6.6 million recorded in 2023.
• Year-over-year, Total Current Liabilities surged 10359.99% in 2022 and slumped 76.2% in 2023.
• Tracing CLDI's Total Current Liabilities over 5 years: stood at $410985.0 in 2021, then surged by 10359.99% to $43.0 million in 2022, then tumbled by 76.2% to $10.2 million in 2023, then retreated by 7.19% to $9.5 million in 2024, then plunged by 58.56% to $3.9 million in 2025.
• The last three Total Current Liabilities figures came in at $3.9 million (Q4 2025), $5.2 million (Q3 2025), and $5.4 million (Q2 2025), per Business Quant data.

Peer Comparison